Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study

Paciullo, Francesco; Menduno, Paola; Tucci, Davide; Caricato, Anna; Cagini, Carlo; Gresele, Paolo

doi:10.1007/s11739-021-02905-7

Cited by 3 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although often unrecognized in the United States, it is associated with low-tension glaucoma, disk hemorrhages, and increased oxidative stress. 60 , 61 There appears to be an overlapping relationship between Flammer Syndrome with low tension glaucoma, retinal venous dysregulation, and increased RVP with increased risk for retinal vascular disease, including RVO. 39 , 62 , 63 Devogelaere and others have specifically shown that subjects with glaucoma and ocular vascular diseases have increased RVP which responds to Ocufolin ® .…”

Section: Discussionmentioning

confidence: 99%

Case series of retinal vein occlusions showing early recovery using oral l-methylfolate

Baker,

Baker

et al. 2024

Ophthalmol Eye Dis

View full text Add to dashboard Cite

This case series describes the aggregate rate of recovery in five consecutive subjects (six eyes) with retinal vein occlusion (RVO) who received l-methylfolate and other vitamins via Ocufolin®, a medical food. Subjects were followed for 10–33 months by a single ophthalmologist. Ocufolin® was prescribed at the time of diagnosis and subjects remained on the regimen throughout the time of observation. Examinations were performed in an un-masked fashion at 3-month intervals with recording of best corrected visual acuity (BCVA), average retinal nerve fiber layer (ARNFL) and central macular thickness (CMT), and fundus (examination of the retina, macula, optic nerve, and vessels) photography. Testing was done for vitamin deficiencies, vascular and coagulable risk factors, and methylenetetrahydrofolate reductase (MTHFR) polymorphisms. Vitamin deficiencies and vascular risk factors were found in all subjects, and all four tested subjects carried at least one MTHFR polymorphism. By the end of the study period BCVA in all subjects was 20/25 or better. Cystoid macular edema was identified and measured by optical coherence tomography (OCT). The percent change was calculated and plotted at 3-month intervals using the percent change in thickness from the time of diagnosis and percent change toward normative values for ARNFL and CMT. The total reduction in thickness of ARNFL and CMT from time of diagnosis was 44.19% and 30.27%, respectively. The comparison to normative data shows a reduction of ARNFL from 164.2% to 94% and CMT from 154.4% to 112.7% of normal thickness (100%). Plots showed the aggregate recovery was most rapid over the first 3 months and slowed over the next 3 months with most of the recovery taking place within 6 months of treatment. The rate of improvement in BCVA and resolution of retinal thickening was found to be better than predicted on historical grounds. No subjects progressed from nonischemic to ischemic RVO. Vitamin deficiencies, vascular risk factors, and genetic predisposition to oxidative stress were common in this RVO series. It appears that addressing these factors with Ocufolin® had a salutary effect on recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Case series of retinal vein occlusions showing early recovery using oral l-methylfolate

Baker,

Baker

et al. 2024

Ophthalmol Eye Dis

View full text Add to dashboard Cite

show abstract

Homozygous MTHFR C667T carriers ≤45 years old develop central retinal vein occlusion five years earlier than wild type

Ames,

Arcaro,

D’Andrea

et al. 2024

Ophthalmic Genetics

View full text Add to dashboard Cite

Retinal Vein Occlusion–Background Knowledge and Foreground Knowledge Prospects—A Review

Lendzioszek,

Bryl,

Poppe

et al. 2024

JCM

View full text Add to dashboard Cite

Thrombosis of retinal veins is one of the most common retinal vascular diseases that may lead to vascular blindness. The latest epidemiological data leave no illusions that the burden on the healthcare system, as impacted by patients with this diagnosis, will increase worldwide. This obliges scientists to search for new therapeutic and diagnostic options. In the 21st century, there has been tremendous progress in retinal imaging techniques, which has facilitated a better understanding of the mechanisms related to the development of retinal vein occlusion (RVO) and its complications, and consequently has enabled the introduction of new treatment methods. Moreover, artificial intelligence (AI) is likely to assist in selecting the best treatment option for patients in the near future. The aim of this comprehensive review is to re-evaluate the old but still relevant data on the RVO and confront them with new studies. The paper will provide a detailed overview of diagnosis, current treatment, prevention, and future therapeutic possibilities regarding RVO, as well as clarifying the mechanism of macular edema in this disease entity.

show abstract

Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study

Cited by 3 publications

References 51 publications

Case series of retinal vein occlusions showing early recovery using oral l-methylfolate

Case series of retinal vein occlusions showing early recovery using oral l-methylfolate

Homozygous MTHFR C667T carriers ≤45 years old develop central retinal vein occlusion five years earlier than wild type

Retinal Vein Occlusion–Background Knowledge and Foreground Knowledge Prospects—A Review

Contact Info

Product

Resources

About